Advertisement

Amyloid Imaging

  • Agostino Chiaravalloti
  • Ferdinando CalabriaEmail author
  • Antonio Bagnato
  • Orazio Schillaci
Chapter

Abstract

Amyloid-imaging agents such as 18F-florbetapir, 18F-flutemetamol, and 18F-florbetaben diffuse across the blood–brain barrier, are taken up in the neuritic plaques, and produce a radioactive signal that is detectable throughout the brain. The highest level of amyloid tracers uptake in the normal brain mostly regards white matter; in the body, they are enhanced in salivary glands, liver, muscles, and bone marrow.

The uptake of amyloid tracers in the gray matter is linked to the deposition of amyloid. Therefore, these tracers are useful for PET and PET/CT imaging of amyloid-related kinds of dementia. In particular, PET with amyloid tracers is useful in evaluating patients with mild cognitive impairment and Alzheimer’s disease. Future studies are needed to clarify the potential added value of these radiopharmaceuticals in evaluation of systemic or cardiac amyloidosis.

Diagnostic pitfalls can be due to rapid washout of tracers in the brain, faint uptake in vascular dementia, or motion artifacts in PET/CT fusion imaging.

Keywords

18F-Flutemetamol 18F-Florbetapir 18F-Florbetaben Alzheimer’s disease Mild cognitive impairment Amyloidosis 

Abbreviations

18F-FDG

18F-Fluorodeoxyglucose

AD

Alzheimer’s disease

MCI

Mild cognitive impairment

PET/CT

Positron emission tomography/computed tomography

SUVR

Standardized uptake value ratio

References

  1. 1.
    Mason NS, Mathis CA, Klunk WE. Positron emission tomography radioligands for in vivo imaging of Aβ plaques. J Labelled Comp Radiopharm. 2013;56:89–95.CrossRefGoogle Scholar
  2. 2.
    Hang W, Oya S, Kung MP, et al. F-18 polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol. 2005;32:799–809.CrossRefGoogle Scholar
  3. 3.
    Wang H, Guo X, Jiang S, et al. Automated synthesis of [18F]Florbetaben as Alzheimer’s disease imaging agent based on a synthesis module system. Appl Radiat Isot. 2013;71:461–46.CrossRefGoogle Scholar
  4. 4.
    Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;10:184–5.CrossRefGoogle Scholar
  5. 5.
    Priller C, Bauer T, Mitteregger G, et al. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;5:7212–21.CrossRefGoogle Scholar
  6. 6.
    Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, et al. Tau PET imaging: present and future directions. Mol Neurodegener. 2017;20:19.CrossRefGoogle Scholar
  7. 7.
    Trembath L, Newell M, Devous MD Sr. Technical considerations in brain amyloid PET imaging with 18F-florbetapir. J Nucl Med Technol. 2015;43:15–184.CrossRefGoogle Scholar
  8. 8.
    Thal DR, Beach TG, Zanette M, et al. Estimation of amyloid distribution by [18F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition. Acta Neuropathol. 2018;136:557–67.CrossRefGoogle Scholar
  9. 9.
    Petersen RC, Waring SC, Smith GE, et al. Predictive value of APOE genotyping in incipient Alzheimer’s disease. Ann New York Acad Sci. 1996;802:58–69.CrossRefGoogle Scholar
  10. 10.
    Ong K, Villemagne VL, Bahar-Fuchs A, et al. (18)F-florbetaben Abeta imaging in mild cognitive impairment. Alzheimers Res Ther. 2013;5:4.CrossRefGoogle Scholar
  11. 11.
    Ong KT, Villemagne VL, Bahar-Fuchs A, et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer’s disease: a prospective outcome study. J Neurol Neurosurg Psychiatry. 2015;86:431–6.CrossRefGoogle Scholar
  12. 12.
    Martínez G, Vernooij RW, Fuentes Padilla P, et al. 18F PET with flutemetamol for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;(22):CD012884.Google Scholar
  13. 13.
    Barthel H, Sabri O. Florbetaben to trace amyloid-beta in the Alzheimer brain by means of PET. J Alzheimers Dis. 2011;26:117–21.CrossRefGoogle Scholar
  14. 14.
    Becker GA, Ichise M, Barthel H, et al. PET quantification of 18F-florbetaben binding to beta-amyloid deposits in human brains. J Nucl Med. 2013;54:723–31.CrossRefGoogle Scholar
  15. 15.
    Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.CrossRefGoogle Scholar
  16. 16.
    Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer disease: phase 3 study. Alzheimers Dement. 2015;28:00060–6.Google Scholar
  17. 17.
    Perani D, Schillaci O, Padovani A, et al. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int. 2014;2014:785039.CrossRefGoogle Scholar
  18. 18.
    Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.CrossRefGoogle Scholar
  19. 19.
    Newberg AB, Arnold SE, Wintering N, et al. Initial clinical comparison of 18F-florbetapir and 18F-FDG PET in patients with Alzheimer disease and controls. J Nucl Med. 2012;53:902–7.CrossRefGoogle Scholar
  20. 20.
    Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–5.CrossRefGoogle Scholar
  21. 21.
    Tiepolt S, Barthel H, Butzke D, et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers. Eur J Nucl Med Mol Imaging. 2013;40:238–44.CrossRefGoogle Scholar
  22. 22.
    Arai A, Kaneta T, Okamura N, et al. Pitfalls of voxel-based amyloid PET analyses for diagnosis of Alzheimer’s disease: artifacts due to non-specific uptake in the white matter and the skull. Tohoku J Exp Med. 2014;234:175–81.CrossRefGoogle Scholar
  23. 23.
    Pelletier-Galarneau M, Abikhzer G, Giraldeau G, et al. Molecular imaging of cardiac amyloidosis. Curr Cardiol Rep. 2019;28:12.CrossRefGoogle Scholar
  24. 24.
    Manwani R, Page J, Lane T, et al. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid. 2018;25:247–52.CrossRefGoogle Scholar
  25. 25.
    Townley RA, Botha H, Graff-Radford J, et al. 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin. 2018;28:897–902.CrossRefGoogle Scholar
  26. 26.
    Rinne JO, Suotunen T, Rummukainen J, et al. [11C]PIB PET is associated with the brain biopsy amyloid-β load in subjects examined for Normal pressure hydrocephalus. J Alzheimers Dis. 2019;67:1343–51.CrossRefGoogle Scholar
  27. 27.
    Jang H, Park SB, Kim Y, et al. Prognostic value of amyloid PET scan in normal pressure hydrocephalus. J Neurol. 2018;265:63–73.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Agostino Chiaravalloti
    • 1
  • Ferdinando Calabria
    • 2
    Email author
  • Antonio Bagnato
    • 2
  • Orazio Schillaci
    • 1
    • 3
  1. 1.Department of Biomedicine and PreventionUniversity “Tor Vergata”RomeItaly
  2. 2.Department of Nuclear Medicine and Theranostics“Mariano Santo” HospitalCosenzaItaly
  3. 3.Department of Nuclear Medicine and Molecular ImagingIRCCS NeuromedPozzilliItaly

Personalised recommendations